Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong
· Delayed Price · Currency is HKD 459.80
-9.40 (-2.00%)
At close: Apr 29, 2026
HKG:6990 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -381.97 | -266.77 | -574.13 | -616.1 | -889.8 |
| Depreciation & Amortization | 100.4 | 91.39 | 75.08 | 67.36 | 22.91 |
| Loss (Gain) From Sale of Assets | 0.12 | 0.15 | 1.49 | -5.42 | 0.01 |
| Loss (Gain) From Sale of Investments | -24.13 | -21.55 | -10.53 | -0.51 | -0.36 |
| Stock-Based Compensation | 170.7 | 148.29 | 123.35 | 19.81 | 6.5 |
| Other Operating Activities | 116.62 | 99.97 | 168.8 | 229.49 | 95.71 |
| Change in Accounts Receivable | -41.81 | -88.97 | -124.37 | -20.13 | 0.24 |
| Change in Inventory | -130.44 | -47.47 | -10.4 | 26.07 | -37.28 |
| Change in Accounts Payable | 271.36 | -50.52 | 252.62 | 50.57 | 90.67 |
| Change in Unearned Revenue | -118.91 | -322.68 | 294.34 | 6.2 | 109.04 |
| Change in Other Net Operating Assets | -72.16 | 28.4 | -136.67 | -28.2 | 116.42 |
| Operating Cash Flow | -180.3 | -429.77 | 59.56 | -270.85 | -485.94 |
| Capital Expenditures | -125.69 | -77.46 | -80.98 | -33.66 | -94.08 |
| Sale of Property, Plant & Equipment | 0 | 0.03 | 0.01 | 6.33 | - |
| Sale (Purchase) of Intangibles | -0.57 | -3.66 | -1.27 | -5.33 | -0.66 |
| Investment in Securities | 537.26 | -740.92 | -943.17 | 0.51 | 0.36 |
| Investing Cash Flow | 411.01 | -822.01 | -1,025 | -32.15 | -94.38 |
| Short-Term Debt Issued | - | - | - | 363 | 225.48 |
| Total Debt Issued | - | - | - | 363 | 225.48 |
| Short-Term Debt Repaid | - | - | -394.04 | -45 | -70 |
| Long-Term Debt Repaid | -43.22 | -54.6 | -66.76 | -1.62 | -1.99 |
| Total Debt Repaid | -43.22 | -54.6 | -460.8 | -46.62 | -71.99 |
| Net Debt Issued (Repaid) | -43.22 | -54.6 | -460.8 | 316.38 | 153.49 |
| Issuance of Common Stock | 1,777 | 1,094 | 2,853 | - | 533.81 |
| Other Financing Activities | -6.16 | -2.29 | -10.01 | -2.93 | -39.99 |
| Financing Cash Flow | 1,728 | 1,037 | 2,382 | 313.45 | 647.32 |
| Foreign Exchange Rate Adjustments | -51.48 | 22.29 | 19.39 | 0.71 | -1.39 |
| Net Cash Flow | 1,907 | -192.27 | 1,436 | 11.17 | 65.6 |
| Free Cash Flow | -305.99 | -507.23 | -21.42 | -304.51 | -580.03 |
| Free Cash Flow Margin | -14.87% | -26.24% | -1.39% | -37.88% | -1794.52% |
| Free Cash Flow Per Share | -1.33 | -2.29 | -0.12 | -3.19 | -6.27 |
| Cash Interest Paid | 6.16 | 2.29 | 10.01 | 2.93 | 39.99 |
| Levered Free Cash Flow | -182.09 | -410.8 | -438.58 | -174.83 | - |
| Unlevered Free Cash Flow | -178.25 | -408.43 | -385.88 | -81.82 | - |
| Change in Working Capital | -162.03 | -481.24 | 275.52 | 34.52 | 279.08 |
Source: S&P Capital IQ. Standard template. Financial Sources.